Thrombotargets Europe S.L.
Thrombotargets Europe S.L. is a privately held, clinical-stage biotechnology company based in Barcelona, Spain, founded in 2005 with a small team of 1-10 employees. Its specific pipeline, technology platform, and current operational status are not documented, and its corporate website is an inactive domain parking page.
- Company typePrivate
- Founded2005
- HeadquartersBarcelona, Spain
- Headcount1–10
- GTM type—
- OfferingServices
Thrombotargets Europe S.L. firmographics
Firmographics- Name
- Thrombotargets Europe S.L.
- Legal name
- Thrombotargets Europe S.L.
- Website
- https://thrombotargets.com
- Company type
- Private
- Founded year
- 2005
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Thrombotargets Europe S.L. is a privately held, clinical-stage biotechnology company based in Barcelona, Spain, founded in 2005 with a small team of 1-10 employees. Its specific pipeline, technology platform, and current operational status are not documented, and its corporate website is an inactive domain parking page.
- Ownership category
- akta.pro rank
Thrombotargets Europe S.L. industry classification
Industry- Product category
- Clinical Stage Biotechnology
- NAICS
- Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Services-Medical Laboratories (8071)
- akta.pro primary industry
- Thrombectomy, Embolic Protection & Stroke Intervention Devices (HLAHAFAJ)
- akta.pro secondary industry
- Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM)
Keywords
Where Thrombotargets Europe S.L. is headquartered
LocationHeadquarters
- HQ city
- Barcelona
- HQ country
- Spain
- HQ region
- Europe
Markets served
Thrombotargets Europe S.L. product offering
Product offeringCore offering
Thrombotargets Europe S.L. is a privately held, clinical-stage biotechnology company. Specific product, pipeline, and service details are not available in the source data, and the company's website currently displays only a Namecheap parking page without substantive corporate content.
Differentiator
Problem solved
Functional benefit
Companies that use Thrombotargets Europe S.L.
Customer profileIdeal customer profiles1 record
Thrombotargets Europe S.L. technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Thrombotargets Europe S.L. competitors and assessment
Company assessmentDirect peers
- Portola Pharmaceuticals: Was a clinical-stage and commercial biotech focused specifically on thrombosis and hematology (andexanet alfa for anticoagulant reversal), the most direct comparator to a thrombosis-focused clinical-stage biotech.
- Inari Medical: Develops thrombectomy and venous thromboembolism devices; directly comparable if Thrombotargets pursues device-based clot removal rather than pharmacologic approaches.
- Penumbra Inc. Market leader in mechanical thrombectomy for stroke and peripheral vascular clot removal; relevant peer given Thrombotargets' clear thrombosis positioning.
Broad incumbents
- Bayer (Xarelto/rivaroxaban): Markets one of the leading direct oral anticoagulants (rivaroxaban/Xarelto); defines the standard-of-care competitive backdrop any thrombosis-targeting biotech must contend with.
- Bristol Myers Squibb / Pfizer (Eliquis/apixaban): Co-marketers of apixaban (Eliquis), the leading DOAC by revenue; represents the dominant incumbent therapeutic that any new thrombosis-targeting asset must differentiate against.
- Boehringer Ingelheim (Pradaxa/dabigatran): Developer and marketer of dabigatran (Pradaxa), one of the foundational DOACs; relevant incumbent comparator in the antithrombotic therapeutic space.
- Daiichi Sankyo (Lixiana/edoxaban): Markets edoxaban (Lixiana/Savaysa), another major DOAC; broad incumbent in the thrombosis treatment category relevant to Thrombotargets' positioning.
- Stryker (Neurovascular): Acquired ischemic stroke thrombectomy leader (Trevo) via its Neurovascular division; broad incumbent that competes with smaller thrombosis-focused players.
Emerging players
- Cerus Corporation: Specialized biotech focused on blood safety and pathogen reduction for transfusion medicine, an adjacent niche that overlaps with thrombo-hematology target space.
- PhaseBio Pharmaceuticals: Clinical-stage small-cap biotech developing targeted therapeutics for cardiovascular and metabolic indications, including antithrombotic programs; comparable scale and stage profile to a hypothetical active Thrombotargets.
Market position
Customer concentration
Thrombotargets Europe S.L. social profiles
Digital presenceThrombotargets Europe S.L. financial estimates
Financial estimateRevenue estimate
Valuation estimate
Thrombotargets Europe S.L. leadership team
Management profileNumber of profiles
Thrombotargets Europe S.L. funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Thrombotargets Europe S.L. M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Thrombotargets Europe S.L.
What does Thrombotargets Europe S.L. do?
Thrombotargets Europe S.L. is a privately held, clinical-stage biotechnology company. Specific product, pipeline, and service details are not available in the source data, and the company's website currently displays only a Namecheap parking page without substantive corporate content.
Is Thrombotargets Europe S.L. a public or private company?
Thrombotargets Europe S.L. is a private company. It is classified as unknown and is currently operating.
When was Thrombotargets Europe S.L. founded?
Thrombotargets Europe S.L. was founded in 2005. It employs 1 to 10 people.
Where is Thrombotargets Europe S.L. based?
Thrombotargets Europe S.L. is headquartered in Barcelona, Spain, in the Europe region.
Who are Thrombotargets Europe S.L.'s main competitors?
Direct peers on record are Portola Pharmaceuticals, Inari Medical and Penumbra Inc.. Broad incumbents are Bayer (Xarelto/rivaroxaban), Bristol Myers Squibb / Pfizer (Eliquis/apixaban), Boehringer Ingelheim (Pradaxa/dabigatran), Daiichi Sankyo (Lixiana/edoxaban) and Stryker (Neurovascular). Emerging players are Cerus Corporation and PhaseBio Pharmaceuticals.
Does Thrombotargets Europe S.L. have an API?
No public API is recorded for Thrombotargets Europe S.L..
What industry is Thrombotargets Europe S.L. in?
Thrombotargets Europe S.L.'s product category is Clinical Stage Biotechnology. Its primary akta.pro industry code is HLAHAFAJ, Thrombectomy, Embolic Protection & Stroke Intervention Devices, with a secondary code of HLAGAHAM, Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC). Its NAICS code is 325412 and its SIC code is 8071.